HRP20241297T1 - Optimizirani sistem domaćina / vektora za stvaranje zaštitnih mono- i viševalentnih podjedinica cjepiva na bazi kvasca kluyveromyces lactis - Google Patents
Optimizirani sistem domaćina / vektora za stvaranje zaštitnih mono- i viševalentnih podjedinica cjepiva na bazi kvasca kluyveromyces lactis Download PDFInfo
- Publication number
- HRP20241297T1 HRP20241297T1 HRP20241297TT HRP20241297T HRP20241297T1 HR P20241297 T1 HRP20241297 T1 HR P20241297T1 HR P20241297T T HRP20241297T T HR P20241297TT HR P20241297 T HRP20241297 T HR P20241297T HR P20241297 T1 HRP20241297 T1 HR P20241297T1
- Authority
- HR
- Croatia
- Prior art keywords
- lactis
- lactis strain
- strain
- locus
- promoter
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/14—Fungi; Culture media therefor
- C12N1/16—Yeasts; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
- C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
- C12N15/815—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts for yeasts other than Saccharomyces
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/542—Mucosal route oral/gastrointestinal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
- C12N2720/00011—Details
- C12N2720/10011—Birnaviridae
- C12N2720/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24311—Pestivirus, e.g. bovine viral diarrhea virus
- C12N2770/24334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Pulmonology (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Botany (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Physiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Dermatology (AREA)
- Nutrition Science (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102017012109.5A DE102017012109A1 (de) | 2017-12-27 | 2017-12-27 | Optimiertes Wirts-/Vektorsystem zur Erzeugung protektiver mono- und multivalenter subunit-Vakzine auf Basis der Hefe Kluyveromyces lactis |
| EP18857443.8A EP3732293B1 (de) | 2017-12-27 | 2018-12-19 | Optimiertes wirts-/vektorsystem zur erzeugung protektiver mono- und multivalenter subunit-vakzine auf basis der hefe kluyveromyces lactis |
| PCT/DE2018/000379 WO2019129321A2 (de) | 2017-12-27 | 2018-12-19 | Optimiertes wirts-/vektorsystem zur erzeugung protektiver mono- und multivalenter subunit-vakzine auf basis der hefe kluyveromyces lactis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20241297T1 true HRP20241297T1 (hr) | 2024-12-20 |
Family
ID=65817691
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20241297TT HRP20241297T1 (hr) | 2017-12-27 | 2018-12-19 | Optimizirani sistem domaćina / vektora za stvaranje zaštitnih mono- i viševalentnih podjedinica cjepiva na bazi kvasca kluyveromyces lactis |
Country Status (18)
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4001417A1 (en) * | 2020-11-13 | 2022-05-25 | serYmun Yeast GmbH | Yeast platform for the production of vaccines |
| WO2026119376A1 (de) | 2024-12-03 | 2026-06-11 | Verovaccines Gmbh | Sedimentations-stabilisierte formulierungen für hefe-basierte vakzine |
| CN119391747B (zh) * | 2024-12-12 | 2025-11-18 | 华中农业大学 | 一种利用马克斯克鲁维酵母制备禽传染性法氏囊病vp2纳米颗粒口服疫苗的方法及应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5830463A (en) | 1993-07-07 | 1998-11-03 | University Technology Corporation | Yeast-based delivery vehicles |
| AU2002225681A1 (en) | 2000-11-15 | 2002-05-27 | Globe Immune, Inc. | Yeast-dentritic cell vaccines and uses thereof |
| JP4914990B2 (ja) | 2002-12-16 | 2012-04-11 | グローブイミューン，インコーポレイテッド | 動物を癌から守るための治療用組成物 |
| KR20070068460A (ko) | 2004-10-18 | 2007-06-29 | 글로브이뮨 | 만성 ｃ형 간염에 대한 효모계 치료 |
| CA2638815A1 (en) | 2006-02-02 | 2007-08-16 | Globeimmune, Inc. | Yeast-based vaccine for inducing an immune response |
| DE102008057451A1 (de) | 2008-11-14 | 2010-05-20 | Martin-Luther-Universität Halle-Wittenberg | Verfahren zur oralen Vakzinierung mittels rekombinanter Hefen |
| ES2660597T3 (es) | 2009-04-17 | 2018-03-23 | Globeimmune, Inc. | Composiciones inmunoterápicas de combinación contra el cáncer y métodos |
| DE102011121069A1 (de) | 2011-12-13 | 2013-06-13 | Martin-Luther-Universität Halle-Wittenberg | Vakzinierung mittels rekombinanter Hefe durch Erzeugung einer protektiven humoralen Immunantwort gegen definierte Antigene |
-
2017
- 2017-12-27 DE DE102017012109.5A patent/DE102017012109A1/de not_active Ceased
-
2018
- 2018-12-19 DK DK18857443.8T patent/DK3732293T3/da active
- 2018-12-19 BR BR112020013245-4A patent/BR112020013245A2/pt unknown
- 2018-12-19 MX MX2020006846A patent/MX2020006846A/es unknown
- 2018-12-19 HU HUE18857443A patent/HUE068358T2/hu unknown
- 2018-12-19 CN CN201880083894.1A patent/CN111801422B/zh active Active
- 2018-12-19 CA CA3086598A patent/CA3086598A1/en active Pending
- 2018-12-19 ES ES18857443T patent/ES2990197T3/es active Active
- 2018-12-19 PT PT188574438T patent/PT3732293T/pt unknown
- 2018-12-19 JP JP2020555291A patent/JP7782951B2/ja active Active
- 2018-12-19 HR HRP20241297TT patent/HRP20241297T1/hr unknown
- 2018-12-19 US US16/958,170 patent/US11905517B2/en active Active
- 2018-12-19 EA EA202091435A patent/EA202091435A1/ru unknown
- 2018-12-19 KR KR1020207021778A patent/KR102704217B1/ko active Active
- 2018-12-19 PL PL18857443.8T patent/PL3732293T3/pl unknown
- 2018-12-19 WO PCT/DE2018/000379 patent/WO2019129321A2/de not_active Ceased
- 2018-12-19 EP EP18857443.8A patent/EP3732293B1/de active Active
- 2018-12-19 DE DE112018006647.9T patent/DE112018006647A5/de not_active Withdrawn
-
2020
- 2020-06-12 ZA ZA2020/03553A patent/ZA202003553B/en unknown
-
2023
- 2023-08-16 JP JP2023132434A patent/JP2023166412A/ja active Pending
- 2023-10-05 US US18/481,345 patent/US12473562B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP3732293A2 (de) | 2020-11-04 |
| CN111801422A (zh) | 2020-10-20 |
| PT3732293T (pt) | 2024-10-09 |
| HUE068358T2 (hu) | 2024-12-28 |
| WO2019129321A3 (de) | 2019-09-12 |
| JP7782951B2 (ja) | 2025-12-09 |
| KR102704217B1 (ko) | 2024-09-09 |
| CN111801422B (zh) | 2024-06-14 |
| WO2019129321A2 (de) | 2019-07-04 |
| ZA202003553B (en) | 2021-06-30 |
| EP3732293B1 (de) | 2024-07-03 |
| MX2020006846A (es) | 2020-11-06 |
| ES2990197T3 (es) | 2024-11-29 |
| DE102017012109A1 (de) | 2019-06-27 |
| PL3732293T3 (pl) | 2024-11-18 |
| DK3732293T3 (da) | 2024-09-23 |
| US20240102031A1 (en) | 2024-03-28 |
| KR20200104367A (ko) | 2020-09-03 |
| US12473562B2 (en) | 2025-11-18 |
| US20210230612A1 (en) | 2021-07-29 |
| EA202091435A1 (ru) | 2020-08-28 |
| US11905517B2 (en) | 2024-02-20 |
| BR112020013245A2 (pt) | 2020-12-01 |
| JP2021508496A (ja) | 2021-03-11 |
| CA3086598A1 (en) | 2019-07-04 |
| JP2023166412A (ja) | 2023-11-21 |
| DE112018006647A5 (de) | 2020-10-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Mancera Gracia et al. | Influenza A virus in swine: epidemiology, challenges and vaccination strategies | |
| de Vries et al. | Viral vector-based influenza vaccines | |
| Plotkin | Vaccines, vaccination, and vaccinology | |
| Bande et al. | Progress and challenges toward the development of vaccines against avian infectious bronchitis | |
| Lo et al. | Comparison of vaccines for induction of heterosubtypic immunity to influenza A virus: cold-adapted vaccine versus DNA prime-adenovirus boost strategies | |
| KR101255016B1 (ko) | 소포성 구내염 바이러스의 상승적 감쇠, 그의 벡터 및 그의 면역원성 조성물 | |
| Ulmer | Influenza DNA vaccines | |
| Stachyra et al. | DNA vaccines against influenza | |
| Arnold et al. | Protective vaccination against infectious bursal disease virus with whole recombinant Kluyveromyces lactis yeast expressing the viral VP2 subunit | |
| JP2017503482A5 (cg-RX-API-DMAC7.html) | ||
| ZA200704088B (en) | Recombinant influenza vectors with tandem transcription units | |
| Vignuzzi et al. | Naked RNA immunization with replicons derived from poliovirus and Semliki Forest virus genomes for the generation of a cytotoxic T cell response against the influenza A virus nucleoprotein | |
| JP2008522621A (ja) | 世界的に流行するトリインフルエンザに対して迅速に応答するためのワクチン | |
| Olszewska et al. | Protective and disease-enhancing immune responses induced by recombinant modified vaccinia Ankara (MVA) expressing respiratory syncytial virus proteins | |
| WO2006073431A3 (en) | Avipox recombinants expressing foot and mouth disease virus genes | |
| Di et al. | The self-assembled nanoparticle-based multi-epitope influenza mRNA vaccine elicits protective immunity against H1N1 and B influenza viruses in mice | |
| Gasparini et al. | Live attenuated influenza vaccine–a review | |
| CN117535322A (zh) | 具有异源抗原的活的减毒黄病毒 | |
| Loomis et al. | Gene-based vaccine approaches for respiratory syncytial virus | |
| JP2021508496A5 (cg-RX-API-DMAC7.html) | ||
| CN102741414B (zh) | 通过重组酵母口服/粘膜接种疫苗的方法 | |
| Kennedy et al. | Update on Influenza Vaccines: needs and progress | |
| Pang et al. | Bovine viral diarrhea virus vaccines: Current advancements, challenges, and future perspectives | |
| CN113164582A (zh) | 嵌合黄病毒丽沙病毒疫苗 | |
| Xie et al. | Advances in vaccinia virus-based vaccine vectors, with applications in flavivirus vaccine development |